To evaluate Non-Small Cell Lung Cancer (NSCLC) patients clinical profile and the outcome after treatment with Gefitinib in Pulmonary Oncology Outpatient Clinic Dr. Soetomo General Hospital, Surabaya, Indonesia.
Primary Objective: To determine the efficacy of Gefitinib in NSCLC patient harboring a positive EGFR mutation. Secondary Objective: To evaluate the subjective response of NSCLC patients harboring a positive EGFR mutation who treated with Gefitinib. Safety Objective: To evaluate the safety and tolerability of Gefitinib in NSCLC patient harboring a positive EGFR mutation.
Study Type
OBSERVATIONAL
Enrollment
70
Dr. Soetomo General Hospital
Surabaya, East Java, Indonesia
RECRUITINGPFS (Progression Free Survival)
Progression Free Survival (PFS) as defined by RECIST 1.1 or attending physician's clinical judgement of clinical progression state
Time frame: through study completion, in average of 1 year
Overall Survival (OS)
Overall Survival (OS) as defined by the date of death certificate given by the attending physician or by other government officials
Time frame: through study completion, in average of 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.